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Research
Exposure to dioxins and related compounds
has been declining in the United States for
over two decades in response to regulatory and
other actions taken to reduce their generation
and emissions into the environment (reviewed
by Hays and Aylward 2003). Estimates of
quantifiable emissions of polychlorinated
dibenzo-p-dioxins and polychlorinated
dibenzofurans (PCDD/PCDFs) and of dioxin-
like polychlorinated biphenyls (PCBs) declined
by a factor of 10 between 1987 and 2000, with
the greatest reduction achieved through the
control of municipal waste incineration [U.S.
Environmental Protection Agency (EPA)
2006]. Overall emissions declines have been
paralleled by severalfold reductions in estimates
of dietary intake (Figure 1) and serum lipid–
adjusted concentrations in the general popu-
lation (reviewed by Hays and Aylward 2003;
Lorber 2002).
The concomitant reduction in human
health risks that have accompanied the
declines in PCDD/PCDF/PCB exposure can
be characterized by comparing past and pre-
sent margins of exposure (MOEs) for different
effects. MOEs are determined by dividing a
point of departure (POD), derived from
dose–response data, by relevant human expo-
sure data. As exposure declines, MOEs
become larger. MOEs do not reflect judg-
ments about safety and are not themselves an
indication of the likelihood of a risk.
Interpreting MOEs in the context of risk
assessment and risk management takes into
account such factors as the slope of the dose–
response relationship in the observable range,
type of effect, mode of action, nature and
extent of associated uncertainties, and human
variation in susceptibility to the response of
concern (Risk Commission 1997). In its
recent draft risk assessment of dioxins, the
U.S. EPA (2003) relied on an MOE approach
to evaluate potential risks from PCDD/
PCDFs based principally on animal data. The
U.S. EPA has so far chosen not to establish a
reference dose or other exposure limit for
PCDD/PCDFs, and no acceptable daily
intake has been established by the U.S. Food
and Drug Administration.
Meanwhile, the U.K. Food Standards
Agency (UKFSA), the Joint Food and
Agriculture Organization/World Health
Organization (FAO/WHO) Expert Committee
on Food Additives (JECFA), and the European
Commission’s Scientiﬁc Committee on Food
(ECSCF) have established tolerable daily,
weekly, or monthly intakes for combined expo-
sures to PCDD/PCDFs based on the most 
sensitive end point observed in laboratory ani-
mals: developmental reproductive effects in
male rats exposed prenatally to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) [ECSCF
2001; JECFA 2001; United Kingdom
Committee on Toxicology (UKCOT) 2001].
These efforts derived from earlier efforts by the
WHO (1998), which pioneered the use of
body burden for risk assessment of dioxins.
Although health protective, those limits are
derived from an animal model with question-
able relevance to human health both qualita-
tively and quantitatively (Charnley and
Kimbrough 2006; Connor and Aylward
2006). The U.S. EPA’s most recent draft risk
assessment of PCDD/PCDFs relies primarily
on laboratory animal data to calculate a series
of MOEs for different effects (U.S. EPA
2003), raising important interspecies dose
metric and toxicity extrapolation issues. 
In the recent evaluations, both the ECSCF
(2001) and JECFA (2001) noted that human
data sets were insufﬁcient for quantitative risk
assessment. However, since these evaluations, a
substantial body of literature examining
human responses to dioxins using measure-
ments of serum lipid concentration as the
marker of exposure has developed. In this
study we explored the use of human data sets
on exposure and noncancer end points in the
context of an MOE approach to risk assess-
ment for PCDD/PCDFs and toxic equivalent
(TEQ)–contributing PCB compounds.
Exposure and response data in this effort are
based on the most commonly used metric in
such studies: serum lipid concentration of
TCDD TEQs as estimated using the WHO
toxic equivalency factors (TEFs) (van den Berg
et al. 1998, 2006). Reliance on circulating
serum lipid concentrations avoids issues asso-
ciated with estimating body burden (estimates
of body burden are highly influenced by
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BACKGROUND: Risk assessment of human environmental exposure to polychlorinated dibenzo-p-
dioxins and dibenzofurans (PCDD/PCDFs) and other dioxin-like compounds is complicated by
several factors, including limitations in measuring intakes because of the low concentrations of
these compounds in foods and the environment and interspecies differences in pharmacokinetics
and responses.
OBJECTIVES: We examined the feasibility of relying directly on human studies of exposure and
potential responses to PCDD/PCDFs and related compounds in terms of measured lipid-adjusted
concentrations to assess margin of exposure (MOE) in a quantitative, benchmark dose
(BMD)–based framework using representative exposure and selected response data sets.
METHODS: We characterize estimated central tendency and upper-bound general U.S. population
lipid-adjusted concentrations of PCDD/PCDFs from the 1970s and early 2000s based on available
data sets. Estimates of benchmark concentrations for three example responses of interest (induction
of cytochrome P4501A2 activity, dental anomalies, and neonatal thyroid hormone alterations) were
derived based on selected human studies.
RESULTS: The exposure data sets indicate that current serum lipid concentrations in young adults
are approximately 6- to 7-fold lower than 1970s-era concentrations. Estimated MOEs for each end
point based on current serum lipid concentrations range from < 10 for neonatal thyroid hormone
concentrations to > 100 for dental anomalies—approximately 6-fold greater than would have
existed during the 1970s.
CONCLUSIONS: Human studies of dioxin exposure and outcomes can be used in a BMD framework
for quantitative assessments of MOE. Incomplete exposure characterization can complicate the use
of such studies in a BMD framework. 
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tions. Environ Health Perspect 116:1344–1351 (2008). doi:10.1289/ehp.11514 available via
http://dx.doi.org/ [Online 16 June 2008]assumptions regarding body fat content and
degree of liver sequestration); provides an
exposure metric that can be assessed directly
(rather than calculated using assumptions);
and is of high biological relevance to a variety
of potential target tissue responses. 
Exposure data are derived from several
sources: analysis of adipose tissue samples col-
lected from young adults of service age during
the Vietnam era (including Vietnam veterans)
during the 1970s (Kang et al. 1990); analysis
of blood samples collected from a representa-
tive sample of the U.S. population from the
National Health and Nutrition Evaluation
Survey (NHANES) conducted in 2001–2002
[National Center for Health Statistics
(NCHS) 2008]; and analysis of blood samples
collected from residents of Michigan studied
as part of an exposure evaluation conducted
by the University of Michigan in 2005
[University of Michigan Dioxin Exposure
Study (UMDES) 2008]. Exposures are com-
pared among age groups and among birth
cohorts. Using lipid-adjusted total dioxin
serum TEQ values as the dose metric allowed
us to compare internal doses based entirely on
human data.
Example data sets on noncancer end points
were chosen to demonstrate various approaches
to using epidemiologic data in a quantitative
risk assessment and on the basis of biological
plausibility and interest in the data sets. End
points include induction of the cytochrome
P450 1A2 (CYP1A2) enzyme among highly
exposed adults who accidentally ate contami-
nated rice oil in Taiwan (the Yucheng cohort)
(Lambert et al. 2006); the occurrence of
developmental dental defects among children
highly exposed to TCDD as a result of the
1976 reactor vessel explosion at a chemical
plant in Seveso, Italy (Alaluusua et al. 2004);
and changes in thyroid hormone measures in
infants exposed to background levels of
PCDDs and PCBs in the Netherlands in the
late 1980s and early 1990s (Koopman-
Esseboom et al. 1994). In each case we deﬁned
a POD using an appropriate benchmark dose
(BMD) approach (U.S. EPA 2000), expressing
dose as serum lipid TEQ. We estimated cur-
rent MOEs for those effects (the margins
between the BMDs and measures of serum
lipid TEQ in the general U.S. population) and
discuss the change in MOE compared to
1970s exposures. 
The objective of this study was to a) pro-
vide an assessment of the degree of change in
lipid-adjusted TEQ concentrations over the
past three decades, and b) demonstrate the use
of example human data sets in an MOE frame-
work for assessing noncancer risks of dioxins
and related compounds. A comprehensive
assessment of the weight of the evidence for the
selected end points and within the full body of
available human data was not conducted and
was outside the scope of this effort. However,
implementation of this MOE approach in a
comprehensive risk assessment for dioxins
would include a weight-of-evidence assessment
as a critical component. 
Methods
Exposure characterization. For this analysis,
we evaluated three data sets to estimate serum
lipid concentrations of PCDDs and PCDFs.
The U.S. EPA conducted the National
Human Adipose Tissue Survey (NHATS)
from 1970 to 1987 to monitor chemicals in
adipose tissue in a statistically representative
sample of U.S. residents. Seventeen PCDD/
PCDFs were measured in a subset of NHATS
tissue sampled between 1971 and 1982 from
36 Vietnam veterans, 79 non-Vietnam veter-
ans, and 80 civilian men who were born
between 1936 and 1954 and were between
20 and 45 years of age at the time of sampling
(this subset was not necessarily statistically rep-
resentative) (Kang et al. 1990). Because no
differences in any congener concentrations
were found among these groups, we used the
entire study group of 195 in the present to
characterize adipose tissue lipid-adjusted con-
centrations of PCDD and PCDF compounds
during the 1970s. No PCB compounds were
measured in that study. We assumed that the
lipid-adjusted adipose tissue concentrations
measured in this study reflect the lipid-
adjusted concentrations in serum in these
individuals (Patterson et al. 1988). 
To determine how congener levels have
changed over time, we compared the results
from the 1971–1982 samples analyzed by
Kang et al. (1990) with recent data from two
data sets. The ﬁrst data set comprises measure-
ments from serum collected for NHANES
2001–2002 (NCHS 2008) and analyzed for
17 PCDD/PCDFs from a subsample of
participants. That study used a complex,
multistage, probability sampling design to
select participants representative of the civilian,
noninstitutionalized U.S. population. Using
analytical guidelines for these data provided by
the National Center for Health Statistics and
the NHANES Program, we analyzed TCDD
and TEQ concentrations in people who were
20–45 years of age in 2001–2002 (to compare
against the similar age group in the 1970–1987
NHATS survey) or were born between 1936
and 1954 [47–66 years of age; i.e., of the same
birth cohort as included in the study by Kang
et al. (1990)]. We used Stata 9.0 (StataCorp,
College Station, TX) to assess percentiles. For
the NHANES data, we used the subsample-
specific sampling weights provided in the
NHANES data sets. 
The second data set of more recent TEQ
determinations comprises measurements taken
in 2005 as part of the UMDES. The study was
focused on assessing potential relationships
between environmental dioxin exposures in
the area of Midland and Saginaw Counties in
Michigan, where elevated concentrations of
PCDD/PCDF compounds have been identi-
fied in soils. The UMDES included a two-
stage random sample of the population of
Jackson and Calhoun Counties in Michigan
(n = 251); these two counties constituted an
external referent population, believed to be
without unusual exposure to PCDD/PCDFs.
This data set provides a key advantage over the
NHANES data set because of the use of far
larger serum volumes with the resulting
increase in analytical sensitivity. The individ-
ual data were not available for analysis, but we
used population-weighted summary data and
statistics available on the study web site
(UMDES 2008). 
We calculated TEQ values for individual
subjects in each study using the 1998 WHO
TEFs for individual congeners (van den Berg
et al. 1998) for PCDD/PCDFs and con-
structed box plots to describe interindividual
variability in serum PCDD/PCDF TEQ
within each data set using Stata 9.0. We used
the 1998 TEF values because the response
data sets evaluated here relied upon those TEF
values (or an earlier version), and the original
data were not available for recalculation.
Dose–response characterization. The gen-
eral approach used in this study was as fol-
lows: first, we assessed a quantitative
relationship between the end point of interest
and measured serum lipid-adjusted TEQ con-
centrations, and then we estimated a dose
associated with a consistent benchmark
response level across studies. For data sets
addressing continuous variables, the bench-
mark response level was set at 10% extra risk
of exceeding the normal range (as discussed,
for example, by Gaylor and Aylward 2004).
In the present study, we identiﬁed the limits
of the normal range as the 2.5th and 97.5th
percentiles in the general population, which
MOE assessment for dioxins using human data
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Figure 1. Estimated dietary intakes of PCDD/PCDFs
in the United States (U.S. EPA 2000; U.S. FDA 2008),
the Netherlands (Liem et al. 2000), the United
Kingdom (UKFSA 2003), Germany (Furst and
Wilmers 1997), and New Zealand (Smith and
Lopipero 2001). New Zealand data represent a
range of estimates based on central and upper-end
intake and concentration estimates. Adapted from
Hays and Aylward (2003).
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New Zealandcorresponds to the typical delineation of clini-
cal reference ranges (Siparsky and Accurso
2007). For data sets addressing quantal end
points, the benchmark response level was like-
wise set to 10% extra risk of the event
(BMD10). These BMD10 values can then be
used as the basis of an assessment of MOE
and changes in the MOE over time in the
general U.S. population. 
For this exploratory analysis, we selected
three end points, each one based on data from
a different study. The selection of these stud-
ies or end points does not represent a conclu-
sion that a causal association between the
exposure and the response has been estab-
lished. End points were selected to be carried
forward for quantitative analysis based on the
biological relevance and plausibility of the end
point examined, previous interest in the study
and population, and as examples of various
types of data that are found in the epidemio-
logic literature. 
CYP1A2 activity. Lambert et al. (2006)
followed a group of people highly exposed to
PCBs and PCDFs due to accidental ingestion
of contaminated rice oil in Taiwan (the
Yucheng cohort). A total of 174 Yucheng and
134 control subjects were studied in an effort
to determine the effectiveness of using induc-
tion of the CYP1 family of enzymes as a bio-
marker of exposure and effect in that cohort.
Because CYP1A2 activity cannot be measured
directly in humans, the caffeine breath test
(CBT), a marker for CYP1A2 activity, was
conducted. 3-N-Demethylation of caffeine is
catalyzed by CYP1A2, so measurement of the
proportion of exhaled 13C-labeled caffeine
metabolites within a given time period (1 hr)
after a known dose of 13C-labeled caffeine
serves as a measure of that enzyme’s activity
(Landi et al. 1999). Increasing enzyme activ-
ity (as reﬂected by increased caffeine metabo-
lism rate) with increasing serum TEQ may
represent aryl hydrocarbon receptor (AhR)-
mediated induction of CYP1A2. These data
constitute an evaluation of TEQ levels that can
alter AhR-mediated gene expression in a
human population as expressed by an early
biochemical response known to be directly
linked to AhR activation. Serum measure-
ments included 17 PCDD/PCDFs and PCBs
77, 81, 126, 169, 105, 118, 156, 157, 167,
and 189. Total dioxin TEQ was calculated
based on the 1998 WHO TEFs (van den Berg
et al. 1998). Lambert et al. (2006) presented a
linear regression of percentage of 13C-labeled
caffeine dose metabolized in an hour versus
parts per trillion serum TEQ. A BMD10 for
CYP1A2 induction was developed using this
regression together with reported information
on CBT variation among the controls. 
Developmental defects of tooth enamel.
Alaluusua et al. (2004) examined developmen-
tal defects of tooth enamel among subjects who
were < 5 years of age (representing the age win-
dow during which development of permanent
teeth occurs) at the time of exposure to TCDD
after the explosion of a trichlorophenol produc-
tion reactor in Seveso in 1976. The end point is
of interest because a number of animal studies
have demonstrated dental defects in rats
exposed during the developmental period
(reviewed by Alaluusua and Lukinmaa 2006)
and because the Seveso population presents one
of the few situations in which well-characterized
exposure to TCDD has occurred in a non-
occupational population. Dental examinations
conducted 25 years after the accident were
reported for 36 individuals who lived within
the ABR zone (the area exposed during the
accident) and 39 individuals who lived outside
the ABR zone. Alaluusua et al. (2004) reported
TCDD levels (but not levels of other dioxin
congeners) for those subjects, based on serum
that had been collected and frozen in 1976, and
presented a categorical analysis by level of meas-
ured serum lipid TCDD in four exposure cate-
gories: non-ABR zone (background exposure),
31–226 ng/kg TCDD, 238–592 ng/kg
TCDD, and 700–26,000 ng/kg TCDD. No
individual measurements of other TEQ-con-
tributing congeners were made in the Seveso
serum samples, and no serum TCDD or TEQ
measurements were available for the reference
individuals. Therefore, we used the concentra-
tions of 17 PCDD/PCDF compounds and
nine TEQ-contributing PCB congeners meas-
ured in pooled serum samples for children
1–12 years of age collected during the 1970s
period from outside the Seveso area as
reported by Eskenazi et al. (2004). We
assumed that Seveso children had similar
serum levels of these non-TCDD congeners at
the time of the accident and therefore esti-
mated non-TCDD TEQ concentrations for
Seveso residents as well as average total TEQ
for the non-ABR reference individuals based
on the data from Eskenazi et al. (2004).
Because exposures are likely to be lognormally
distributed, we took the antilog of the average
of the log of the minimum and maximum of
each categorical exposure range to represent a
central estimate of exposure within each cate-
gory. We conducted BMD modeling to esti-
mate the serum lipid TEQ concentration
corresponding to a 10% extra risk of dental
defects using U.S. EPA Benchmark Dose
Software [BMDS, version 1.4.1b (U.S. EPA,
Washington, DC) with a variety of dichoto-
mous models, with slopes restricted to be non-
negative to allow for the possibility of nonzero
defect levels at zero exposure].
Thyroid hormone concentrations in
infants. Koopman-Esseboom et al. (1994)
examined thyroid hormone levels in 78
2-week-old infants from the general popula-
tion in Rotterdam (the Netherlands) between
1990 and 1992 and related them to TEQ in
their mothers’ milk (which was considered to
represent lipid-adjusted TEQ of the mother
and therefore a marker for in utero exposure
levels). The mother–infant pairs were divided
into two exposure groups: low (maternal milk
TEQ less than or equal to the median,
72.43 pg TEQ/g lipid) and high (maternal
milk TEQ > 72.43 pg TEQ/g lipid), and the
mean and SE of infant free thyroxine (FT4)
concentrations were reported for each group.
Based on the reported mean, median, and SD
of maternal TEQ concentration and assuming
an overall lognormal distribution of TEQ con-
centrations in maternal milk, we estimated the
mean milk TEQ concentrations in the lower
and upper exposure groups and assumed a
simple linear relationship between maternal
milk TEQ and infant FT4 concentrations. We
assume that the population variation in FT4 at
any particular TEQ level is normally distrib-
uted with a degree of variability around its
mean that is independent of TEQ and is equal
to the average of the reported standard devia-
tions of FT4 within each of the two exposure
groups (low and high). The effect of TEQ on
mean FT4 is calculated by the regression line
between the high and low exposure groups.
We assumed that maternal milk lipid-adjusted
TEQ concentrations reflect maternal serum
TEQ concentrations, an assumption that
appears to be approximately correct, although
some differential partitioning between breast
and serum lipids occurs for higher chlorinated
congeners (Wittsiepe et al. 2007). This differ-
ential partitioning likely has a limited effect on
total TEQ in human serum and milk because
of the relatively low contribution of higher
chlorinated congeners.
Characterization of changes in MOE. The
MOE in a population is a unitless ratio
between the POD and the estimate of dose or
exposure in that population:
.[ 1 ]
For this effort, both the POD and current
exposure estimates are presented in terms of
lipid-adjusted TEQ (WHO 1998) concentra-
tion. We also present an estimate of the cur-
rent MOE, as well as a discussion of change
in MOE from the 1970s era. 
Results
Exposure. The adipose tissue samples analyzed
by Kang et al. (1990) do not represent either a
speciﬁc sampling year or speciﬁc age group but
can generally be described as representing
1970s TEQ concentrations in males born
between 1936 and 1954 (with a general age
range at that time of 20–45 years). Descriptive
statistics on the distribution of lipid-adjusted
TEQ concentrations [using the WHO TEF
values (WHO 1998)] are presented in Table 1
MOE
POD
Dose
=
Aylward et al.
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limits (LODs) was provided, and nondetects
were included in the calculations as zero. Thus,
the calculated TEQ concentrations may under-
estimate actual concentrations for this age
group during this time period. 
The results of the analysis of the NHANES
data set for PCDD/PCDF TEQ are also pre-
sented in Table 1. Data were analyzed for two
groups: a) adults 20–45 years of age at the time
of the 2001–2002 sampling effort, and
b) adults who were born between 1936 and
1954. These two groups correspond to the age
range and birth cohort, respectively, included
in the Kang et al. (1990) data set. Because the
NHANES data set relied on very small serum
sampling volumes, limits of detection (LODs)
were quite high for many congeners. Ferriby
et al. (2007) demonstrated that, particularly for
individuals with relatively lower concentrations
(for example, younger individuals), the choice
of how to replace nondetected concentrations
in TEQ calculations could affect estimated
TEQs by 50–100%. We used two approaches,
estimating percentiles under the assumption
that nondetectable concentrations were zero (as
used for the Kang et al. data set, for which no
information on LODs was available) and
assuming that nondetects were equivalent to
the LOD/
–
2. For the younger age groups,
choice of replacement for nondetectable con-
centrations results in nearly a 100% increase in
the estimate of current median serum lipid
concentrations. Upper-bound estimates are less
sensitive to the assumption. 
The data from the UMDES study refer-
ence population (Jackson and Calhoun coun-
ties, sampled in 2005) are available only in
summary form for speciﬁc age groups (18–29,
30–44, 45–59, and ≥ 60 years). These age
breakdowns allow a fairly direct comparison
for the 20- to 45-year age group but are less
useful for describing the concentrations in
individuals born between 1936 and 1954
(51–69 years of age in 2005), particularly
because of the substantial age-related changes
in serum dioxin concentrations in persons
> 40 years of age (Ferriby et al. 2007).
Summary statistics for the relevant overlapping
age groups from the UMDES study are also
presented in Table 1. Because substantial
serum volumes were available for all analyses,
TEQ estimates are not affected substantially by
the presence of nondetectable concentrations.
Figure 2 presents box plots comparing
the 1970s data with the current data sets for
persons 20–45 years of age during both time
periods (Figure 2A) and for persons born
during the 1936–1954 period over time
(Figure 2B). Within individuals born between
1936 and 1954, both median and 95th per-
centile PCDD/PCDF TEQ concentrations
between the 1970s-era sampling and the
NHANES 2001–2002 sampling years
decreased by approximately 75%. Serum lipid
TEQ concentrations in persons 20–45 years of
age in the 2001–2002 NHANES data set
decreased by approximately 85% compared
with the 1970s-era sampling, a difference
reflected in both the medians and 95th per-
centiles. These comparisons do not include
PCB contributors to TEQ, but a comparison
of wet-weight serum PCB concentrations
observed in studies conducted in the 1970s
(Kreiss 1985) with results from the NHANES
2001–2002 data sets (Nichols et al. 2007) sug-
gests a similar or larger magnitude of decline in
serum PCB concentrations over the same
period, although no statistically representative
data sets are available to specifically assess
changes in TEQ-contributing PCB congener
concentrations over that period. 
The decrease in serum lipid TEQ observed
among persons born between 1936 and 1954
indicates that ambient exposures have declined
substantially since the 1970s. Because the
elimination of PCDD/PCDF compounds
occurs with half-lives on the order of
5–10 years, declines in serum lipid TEQ will
continue for many years after decreases in
exposure levels (Aylward and Hays 2002;
Lorber 2002). As a result, serum TEQ con-
centrations in the population in the future will
likely decline further, and evaluations of MOE
for the purposes of assessing potential risks
from current intake rates should be based on
measured concentrations in younger individu-
als with the least impact from historically
higher exposure levels. As discussed above, the
UMDES study appears to provide the most
reliable data set for characterizing current
serum concentrations in young adults because
of the very low LODs attained in that study.
The median and 95th percentile total TEQ
[according to the WHO 1998 TEF scheme
(WHO 1998), including PCB contributors to
TEQ] reported for the UMDES study referent
population 18–29 years of age based on 2005
sampling are 9.2 and 13.3 ppt TEQ, respec-
tively. These concentrations are used below to
characterize current MOE in the young adult
population of reproductive age in the United
States, a population of high interest for risk
assessment of dioxins.
Response benchmark characterization.
CYP1A2 induction. Lambert et al. (2006) pre-
sented a linear regression of percentage of
13C-labeled caffeine dose metabolized in an
MOE assessment for dioxins using human data
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Table 1. Median (95th percentile) of measured lipid-adjusted PCDD/PCDF TEQ concentrations from sam-
pling conducted in the United States in the 1970s and 2001–2005.
WHO 1998 TEQ, PCDD/PCDF
Sampling year(s) ND = 0 ND = LOD/
–
2
Birth cohort, 1936–1954
NHATS 1971–1982 60.2 (151.1)
NHANES  2001–2002 12.4 (43.5) 17.2 (44.5)
UMDES referents, birth year < 1940 2005 25.7 (46.7)
UMDES referents, birth years 1940–1960 2005 17.6 (30.1)
Adults 20–45 years of age
NHATS 1971–1982 60.2 (151.1)
NHANES, ages 20–45 years 2001–2002 5.9 (22.4) 11.7 (26.7)
UMDES referents, ages 18–29 years 2005 7.0 (9.7)
UMDES referents, ages 30–44 years 2005 12.2 (20.2)
ND, nondetects. NHATS data from Kang et al. (1990).
Figure 2. Box plots illustrating the distribution of measured PCDD/PCDF TEQ (WHO 1998) concentrations in
samples from individuals age 20 to 45 years of age (A) or born between 1936 and 1954 (B) in the general
population in the United States. Boxes represent the interquartile range (25th–75th percentiles; median
indicated by horizontal line), and whiskers extend to the 5th and 95th percentiles. NHATS, lipid-adjusted
adipose tissue concentrations from NHATS samples collected between 1971 and 1982 (Kang et al. 1990);
NHANES, lipid-adjusted serum concentrations from the NHANES 2001–2002 survey assuming nondetects
are present at LOD/
–
2; UMDES, lipid-adjusted serum concentrations from samples collected in 2005 from
residents of referent counties in Michigan (UMDES 2008); 5th and 25th percentiles were not reported from
this study and so are not included in the box plots here. 
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[WHO 1998 TEQ (WHO 1998)] with a
reported slope of 0.0029 and an intercept of
1.17% of dose metabolized. An estimate of the
pooled (male and female) weighted average
and SD of CBT in the 134 controls can be
derived from data (1.18% ± 1.20) of the CBT
in male and female controls of Lambert et al.
(2006). If the distribution of CBT is normal,
then the 97.5th percentile of the amount
metabolized in 1 hr is approximately 3.5%;
this appears to be generally consistent with the
data presented in graphical form by Lambert
et al. (2006). 
Assuming that this degree of inter-
individual variability applies at any specific
dioxin serum level [as appears reasonable from
examination of Lambert et al.’s Figure 1
(Lambert et al. 2006)], then a BMD10 can be
calculated as the serum TEQ necessary to shift
the distribution such that an additional 10% of
the population has a CBT exceeding 3.5%.
Using the regression equation calculated by
Lambert et al. (2006) and the assumption of
normal variability in the CBT outcome around
its mean value yields an estimate of serum
TEQ BMD10 of approximately 340 ng/kg
lipid. Assumption of lognormal distribution of
values around the mean results in a BMD10
estimate of approximately 400 ppt TEQ. 
Dental defects. Table 2 presents the
prevalence of dental aberrations, the measured
TCDD and estimated serum lipid TEQ
ranges, and estimated midpoint TEQ concen-
trations, by category, from Alaluusua et al.
(2004). The results of BMD modeling for the
data set are presented in Table 3. The log-
logistic model produced the best fit to the
data [i.e., the lowest Akaike information crite-
rion (AIC) value], and three of the models
resulted in slightly higher BMD10 estimates.
Thyroid hormone concentrations. For the
dose–response analysis for FT4 from
Koopman-Esseboom et al. (1994), we esti-
mated mean exposures for both exposure
groups. Koopman-Esseboom et al. (1994)
reported maternal milk TEQ concentrations
using the 1993 WHO TEF values. However,
the changes in the WHO TEF values between
1993 and 1998 result in offsetting changes in
estimates of TEQ (approximately a 15%
increase in estimates of PCDD/PCDF TEQ,
and a similar decrease in PCB TEQ estimates
at the mean because of the changes in TEF
values between the two versions of the TEF
system). Thus, the TEQ concentrations
reported by Koopman-Esseboom et al. (1994)
are used directly in this analysis, on the
assumption that the WHO 1998 TEQ
(WHO 1998), if it could be calculated from
the reported data, would be expected to be
similar. Because the mother–infant pairs were
drawn from the local population without prior
knowledge of exposure, we assumed a lognor-
mal distribution. Using the arithmetic mean
(74.86 pg TEQ/kg lipid) and SD (26.19) for
milk TEQ reported for the overall cohort, we
calculated a geometric mean (70.66 pg
TEQ/kg lipid) and geometric SD (1.405).
This estimated geometric mean corresponds
well with the reported median of 72.43 pg
TEQ/kg lipid, and the lognormal assumption
predicts the observed range of the milk TEQ
values well. Assuming this lognormal distribu-
tion for the overall cohort, mean TEQs for the
low- and high-exposure groups were estimated
to be 56.3 pg TEQ/g lipid and 97 pg TEQ/g
lipid, respectively, as illustrated in Figure 3.
Assuming that the relationship between
FT4 and milk TEQ is linear, the two calcu-
lated mean exposure levels and corresponding
means of the measured FT4 concentrations for
the low- and high-exposure groups define a
regression line; increasing levels of TEQ were
associated with decreasing levels of FT4. The
slope of the regression line is –0.0392 pmol/L
per 1 pg TEQ/g lipid in milk, and the inter-
cept is 26.8 pmol/L. 
For a given TEQ there will be natural
variation in FT4 levels among infants. SDs for
measured FT4 concentrations were given by
Koopman-Esseboom et al. (1994) as
3.5 pmol/L for the low-exposure group and
3.3 pmol/L for the high-exposure group. The
BMD10 is defined in this case as the TEQ
exposure that would change the mean FT4
such that an additional 10% of the variable
population drops below the FT4 level that
constitutes the 2.5th percentile in an unex-
posed population (with zero exposure). To do
this, we assume that the population variation
in FT4 at each exposure level is normally dis-
tributed with a mean calculated by the regres-
sion line and a standard deviation calculated
as the average of the standard deviations for
the two measured data points, namely (3.5 +
3.3)/2 = 3.4 pmol/L. We assume further
that the variability around the regression is
independent of TEQ.
At an exposure level of zero TEQ, the
mean FT4 is estimated to be 26.8 pmol/L (the
regression line intercept), and using the
observed SD of 3.4 pmol/L (mean of the two
provided SDs), the 2.5th percentile FT4 level is
20.1 pmol/L. This value is consistent with
published neonatal thyroid hormone reference
ranges (Hubner et al. 2002). The BMD10 is
then the TEQ exposure at which an extra 10%
of the population has FT4 concentrations
≤ 20.1 pmol/L, which occurs when the mean
FT4 concentration is 24.0 pmol/L and corre-
sponds to a BMD10 of approximately 70 pg
TEQ/g lipid in milk. 
MOE characterization. The BMD10 val-
ues calculated for each end point are presented
in Table 4. These values are best estimates
from the specific studies and data sets using
the assumptions outlined in this manuscript
and are provided as examples of potential
quantitative approaches to a variety of epi-
demiologic data sets that are available. Table 4
also provides an overview of the estimated
margins of exposure for each of the end points
Aylward et al.
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Table 2. Developmental defects of enamel in individuals who were children (< 5 years of age) at the time of
the Seveso accident, referents, and Seveso residents by tertile. 
Estimated median 
Range of serum TCDD TCDD concentration Estimated TEQ 
Exposure group (n) (ng/kg lipid) (ng/kg lipid)a (ng/kg lipid)b Prevalence (%)
Non-ABR subjects (39) NM 40.5 116.6 10 (26)
Seveso 
1st tertile (10) 31–226 83.7 159.8 1 (10)
2nd tertile (11) 238–592 375.4 451.5 5 (45)
3rd tertile (15) 700–26,000 4266.1 4342.2 9 (60)
NM, not measured. Data from Alaluusua et al. (2004)
aAssumes lognormal distribution of serum TCDD measurements (see “Methods”). bEstimated based on data from
Eskenazi et al. (2004). Average non-TCDD TEQ (16 PCDD/PCDF and 9 PCB compounds) measured in two pooled serum
samples from children 1–12 years of age from outside Seveso collected during the same time period was 76.1 ng TEQ/kg
lipid; this value was added to estimated median TCDD values for each Seveso exposure group. Total TEQ (including back-
ground TCDD) averaged 116.6 ng/kg TEQ in the two pooled samples; this value was used as the TEQ concentration for the
non-ABR referents. 
Table 3. BMD10 modeling results for dental defects. 
Model BMD10 BMDL10 AIC
Gamma (power ≥ 1) 666.2 330.8 93.1582
Log-logistic (slope ≥ 1) 445.3 140.1 92.9532
Multistage (1-degree,  666.2 330.8 93.1582
beta ≥ 0)
Probit (slope ≥ 1) 1296.9 636.3 93.6437
Weibull (power ≥ 1) 666.2 330.8 93.1582
BMDL10, statistical lower bound on the BMD10. Data from
Alaluusua et al. (2004). 
Figure 3. Estimated probability distribution of lipid-
adjusted human milk concentrations from Koopman-
Esseboom et al. (1994) based on summary statistics
discussed in the text. 
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(97 pg/g fat)based on estimates of current serum lipid
TEQ concentration (including PCDD/PCDF
and PCB compounds) in young adults at
the median and at the 95th percentile. MOEs
for the same end points in the 1970s would
have been approximately six to seven times
lower, based on the comparative exposure data
summarized above. 
Discussion
Consideration of target MOE. The MOE
estimates presented in Table 4 can be com-
pared with a target minimal MOE related to
the usual application of uncertainty factors in
the derivation of reference doses, minimal risk
levels, and other benchmarks for general
population environmental exposures. Table 5
outlines the typical uncertainty factors applied
and provides a discussion of the applicability
of such factors to a risk assessment based on
human data using an internal measure of bio-
logically relevant exposures. Selection of a tar-
get MOE requires a judgment regarding the
biological relevance or adversity of the mod-
eled benchmark response, so that larger or
smaller components of the lowest observed
adverse effect level (LOAEL) to no observed
adverse effect level (NOAEL) uncertainty fac-
tor might be selected for a given end point or
selected benchmark response level (e.g., a
10% increase in the proportion of the popula-
tion exhibiting increased enzyme activity
might be considered a less adverse benchmark
than a 10% increase in the proportion
exhibiting decreased FT4 concentrations).
Because both the dose–response assessment
and the exposure assessments for this evalua-
tion are based upon biologically relevant
internal dose metrics (circulating serum TEQ
concentration), the uncertainty factor compo-
nent typically applied for intraspecies toxico-
kinetic differences is replaced by the actual
sampling data in the population, which explic-
itly reflects the variations in toxicokinetics
among individuals. That is, individuals who
are pharmacokinetically sensitive (presumably
those who eliminate the compounds more
slowly) directly reflect this sensitivity in the
measured serum lipid concentrations, which
will be higher than those in the less-sensitive
members of the population. 
The current MOEs estimated for CYP1A2
and for dental defects are generally above the
range of target minimal MOEs, suggesting that
these end points may not be of concern at cur-
rent background serum concentrations.
However, the current MOEs for thyroid hor-
mone alterations in infants based on the
Koopman-Esseboom et al. (1994) data and
current U.S. exposure data are at the lower end
of the range of target MOE values, although
there is a clear separation between current U.S.
concentrations in young adults of reproductive
age and the BMD10 for this end point. That is,
the current upper-bound TEQ concentration
in young adults of reproductive age in the
United States (~ 14 ppt TEQ) is approxi-
mately 5-fold lower than the BMD10. Recent
studies of this end point provide conflicting
results: Maervoet et al. (2007), in a study of
140 Flemish infants, report an association
between maternal serum TEQ and umbilical
cord FT4 of similar magnitude, whereas
Wilhelm et al. (2008) report no relation
between maternal milk or blood TEQ and
cord blood thyroid hormone concentrations in
a smaller study of German infants. Other
researchers have also found conﬂicting results
[reviewed by Giacomini et al. (2006) and
Maervoet et al. (2007)]. The high degree of
correlation between serum TEQ and non–
TEQ-contributing organochlorine compounds
complicates the identiﬁcation of causal agents
and relationships. Other factors not typically
controlled for in such studies, such as gesta-
tional age and serum lipid concentration, may
also confound the relationships observed
(reviewed by Maervoet et al. 2007). 
The BMD10 estimates presented here in
terms of serum lipid TEQ can be compared
with the adipose tissue concentrations reported
in key animal studies previously used to derive
the JECFA (2001), UKCOT (2001), and
ECSCF (2001) tolerable daily intakes.
Maternal wet-weight adipose tissue concentra-
tions in the key studies at the LOAELs or
NOAELs can be estimated as ranging from
approximately 65 to 200 ppt TCDD (Faqi
et al. 1998; Hurst et al. 2000). If these wet-
weight concentrations are adjusted assuming
80% lipid content of adipose tissue, these cor-
respond to approximately 80–250 ppt TEQ,
comparable to the range of BMDs derived here
(Table 4).
The assessment of current exposures based
on measured serum lipid concentration has
several strengths over conventional exposure
assessments based on intake. Such measure-
ments aggregate exposure from all exposure
routes and media, which individually may be
difﬁcult to quantify because of low concentra-
tions. Reliance on measured serum concentra-
tions also reduces uncertainties in risk
assessment regarding potential interindividual
pharmacokinetic differences, because such
differences are directly reflected in the mea-
sured concentrations. Finally, circulating
serum lipid concentration is likely to be a
good surrogate for critical target tissue expo-
sure concentrations in a range of organs and
tissues because of the lipophilic nature of
dioxin-like compounds. 
When interpreting these results, some lim-
itations inherent in the use of measured TEQ
concentrations for exposure quantification
should be borne in mind. The TEF system
was developed based on relative potencies on
the basis of intake, not tissue concentration.
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Table 4. Summary of modeled BMD10 values and estimated MOEs at the median and upper bound of cur-
rent lipid-adjusted TEQ concentrations in young adults of reproductive age in the United States for three
end points based on example data sets.
MOEa
BMD10 At median current At 95th percentile current
End point (ng TEQ/kg lipid) U.S. TEQ (9.2 ppt) U.S. TEQ (13.3 ppt)
CYP1A2 activity 340 35 25
Dental defects 450–1,300b 50–140 30–95
Neonatal FT4 changes 70 8 5
aCompared with current median and 95th percentile exposures as estimated by UMDES reference population 18–29 years of
age, 29 PCDD/PCDF and PCB congeners, and the WHO 1998 TEQ. bRange of BMD10 estimates from different BMD models. 
Table 5. Evaluation of typical uncertainty factor components in the context of identiﬁcation of target mini-
mal MOE for risk assessments based on human studies employing serum lipid TEQ concentrations as the
exposure metric.
Uncertainty factor component Typical value Applicable? Target value
LOAEL to NOAEL ≤ 10 Data-dependent. Depending on the benchmark  Varies by
chosen, the POD may be regarded  end point
as more similar to a NOAEL or a minimal or frank LOAEL. 1–10
Interspecies 10 No. Risk assessment based on human data. 1
Intraspecies PK 3 No. Interindividual variations in pharmacokinetics  1
are directly reﬂected in measured serum lipid TEQ 
concentrations. Pharmacokinetically “sensitive”
individuals will manifest higher measured 
concentrations, so the sensitivity is reﬂected directly 
in the exposure assessment.
Intraspecies PD 3 Yes, although if the study used as the basis of the  1–3
BMD determination includes the sensitive subpopulation,
this value may be reduced.
Target MOE 1–30
Abbreviations: LOAEL, lowest observed adverse effect level; NOAEL, no observed adverse effect level; PD, pharmaco-
dynamic; PK, pharmacokinetic. Thus, differential toxicokinetics among con-
geners can lead to distortions in the estimate
of total toxic equivalency when TEQ is
assessed on a tissue concentration basis rather
than an intake basis. Such distortions might
be of limited concern when the dose–response
assessment is conducted on populations with
similar distributions of congeners as the cur-
rent background population. However, for
two of the data sets used here, the data from
Lambert et al. (2006) on CYP1A2 activity
and the Seveso data on dental defects
(Alaluusua et al. 2004), the TEQ tissue con-
centrations resulted from unusual exposures
to congeners or mixtures that are not reflec-
tive of background exposure patterns, and
thus extrapolation of responses observed in
those populations to background exposures
on a serum TEQ concentration basis may
pose additional uncertainties. 
Interpretation of results from epidemio-
logic studies must proceed cautiously because
of the complexities inherent in such studies:
cross-sectional epidemiologic studies are not
analogous to toxicologic experiments, and data
from single studies cannot be interpreted in
isolation. Numerous factors outlined by Hill
(1965), including consistency of evidence
across studies, biological plausibility, and
accounting for potential confounding, must be
assessed. The three examples presented here
represent data sets on end points with varying
degrees of consistency in the epidemiologic
literature. Induction of CYP1A2 activity in
humans has been observed previously in
individuals with highly elevated exposures
[reviewed by Connor and Aylward (2006)],
and the magnitude of dose response reported
by Lambert et al. (2006) is consistent with pre-
vious reports. The pattern of evidence related
to potential impacts of dioxin-like compounds
on infant thyroid hormone levels is less consis-
tent, as discussed above. The dental anomalies
reported by Alaluusua et al. (2004) in Seveso
children are biologically plausible based on
results from studies in rodents, and data from
the Seveso study and other studies support a
conclusion that exposures above current back-
ground exposures would be required to induce
such effects (Alaluusua and Lukinmaa 2006).
The data sets used to characterize dose
response in this exercise are typical of many
epidemiologic studies in that data are not
generally presented in a framework that
allows direct application of quantitative risk
assessment methodologies. Several common
epidemiologic methods used in such studies
pose challenges in the risk assessment context: 
• When exposures and responses are pre-
sented in categorical analyses [for example,
in the analyses by Koopman-Esseboom et al.
(1994) and Alaluusua et al. (2004)], evalua-
tion of dose response and identification of
BMDs require numerous assumptions
regarding representative exposures in each
category. For example, in the assessment of
the dental defect data for Seveso, we esti-
mated the median TCDD concentration in
each exposure category based on an assump-
tion of an overall lognormal distribution of
exposures. However, other assumptions
could have been used, and the estimated
BMD values would change accordingly. 
•In continuous analyses, full regression
results are often not reported, making it dif-
ﬁcult to estimate BMDs at appropriate val-
ues of important covariates. In addition,
such regressions typically impose a shape on
the ﬁtted dose–response curve, including an
assumption of linearity that extends to the
lowest exposure levels. Because the slope of
a linear regression is often dominated by
responses at the higher end of exposures, the
possibility of a zero slope at lower exposures
(in effect, the existence of a threshold for
the response) is masked in the regression.
• Characterization of the interindividual vari-
ability in the response parameter of interest,
including description of the distribution
type (normal, lognormal) and the magnitude
of typical variability, is often lacking. In par-
ticular, information sufficient to evaluate
interindividual variability in a parameter in
the absence of the inﬂuence of the exposure
of interest is generally not provided. 
• In many epidemiologic studies, results are
reported as odds ratios. Conversion of rela-
tionships reported in this way into continu-
ous functions that can be used to estimate
BMDs can be difficult or impossible,
depending upon what other information is
provided.
• Similarly, epidemiologic studies often report
results using analyses based on logarithmically
transformed exposure measures. Such results
are difﬁcult to extrapolate beyond the range of
the experimental data with any conﬁdence.
For example, such dose–response functions
imply that a change in exposure from 0.1 to
0.3 ppt TEQ might be associated with the
same magnitude of response as an increase in
exposure from 100 to 300 ppt, which may
not be biologically plausible. When attempt-
ing to estimate background responses, such
functions may not be appropriate for extrapo-
lation from higher exposures.
A comprehensive risk assessment effort
based on the available human data sets would
require a systematic assessment of the consis-
tency and weight of the evidence and human
relevance of each end point before quantita-
tive analysis of the data sets was conducted.
Quantitative analysis could then proceed on
end points with strong or moderate levels of
evidence to provide a full quantitative context
for interpretation of exposure data. 
The analysis presented here demonstrates
that young adults in the U.S. population have
current serum TEQ concentrations ≥ 6-fold
lower than adults of the same age in the 1970s.
Thus, the margins of exposure for all potential
effects of dioxin-like compounds have
increased by a factor of six over the past three
decades. Because a substantial body of epi-
demiologic studies of potential health impacts
of dioxins relying upon measured serum TEQ
as the exposure metric now exists, such expo-
sure data can be used directly in the risk assess-
ment arena to assess margins of exposure for
responses of interest. Some uncertainties arise
in using such data in a risk assessment context
because of limitations in reporting exposure or
response parameters in such studies. However,
application of risk assessment methodologies to
this body of epidemiologic data avoids uncer-
tainties inherent in interspecies extrapolation
and in accounting for pharmacokinetic vari-
ability that may result in differential impacts of
a given estimated intake dose. 
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